The Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation provides clinical consultation and research programs aimed at making the use of medications in children safer and more effective. Within the division, the Section of Medical Toxicology provides consultative services for potential poison exposures, including overdoses, environmental exposures, and envenomations.
Pharmacology and Toxicology Staff
The division includes physicians, doctoral-trained researchers, fellows, nurses, research coordinators, research assistants, administrative staff, trainees and students. Several faculty members are credentialed in Clinical Pharmacology by the American Board of Clinical Pharmacology; others have completed their pediatric clinical pharmacology fellowship at Children's Mercy in the Division as a joint program with other pediatric subspecialties.
Our work has allowed the division to achieve an international reputation as a leader in pediatric clinical pharmacology and medical toxicology.
Individualized Pediatric Therapeutics (IPT) is designed to serve as a multi-disciplinary resource in therapeutics for patients and providers within the Children’s Mercy system. This clinic will serve patients with complex therapeutic dilemmas who are referred by their primary care physician or sub-specialist. The clinic will implement a team approach in addressing the facets of therapeutic response which are unique to each patient. This will include a weekly comprehensive case discussion of each patient with a team of physicians, researchers, and pharmacists. Recommendations may include follow-up, adjustments to the care plan, and/or additional testing.
PEHSU National Classroom
The Pediatric Environmental Health Specialty Unit is dedicated to increasing knowledge about environmental medicine amongst healthcare professionals regarding children’s environmental health. Visit this link for a description of the opportunities that PEHSU Offers.
Learn more about the PEHSU National Classroom
GOLDILOKS stands for Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for KidS. Children's Mercy has received a five-year grant from the National Institutes of Health that will support continued development of the program, which is designed to ensure that children receive the precise dose of medicine they need, when they need it. The initial focus will be on a medication used to treat attention-deficit/hyperactivity disorder for which genetic variation is known to have a substantial effect on how much drug is present in the body after dosing.
Through collaborations with partners at the University of Manchester, Duke University, and other academic institutions, the GOLDILOKs Center will add internationally recognized expertise in quantitative systems biology and metabolomics to improve the health and well-being of children everywhere.